ArticleCancer chemotherapy and pharmacology2019

Phase I study of ipatasertib as a single agent and in combination with abiraterone plus prednisolone in Japanese patients with advanced solid tumors.

Toshihiko Doi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.